Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)

Dahlqvist, Sofia; Ahlén, Elsa; Filipsson, Karin; Gustafsson, Thomas; Hirsch, Irl B.; Tuomilehto, Jaakko; Imberg, Henrik; Åhrén, Bo; Attvall, Stig; Lind, Marcus

doi:10.1136/bmjdrc-2017-000464

Cited by 19 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subjects with the highest HbA1c at baseline lost less weight than those with lower HbA1c at baseline, albeit with clinically relevant absolute weight loss. A similar pattern, with less weight loss in subjects with higher baseline HbA1c levels, was also observed with dulaglutide in the AWARD programme, and with liraglutide . These findings may be a result of treatment‐related increases in glycaemic control.…”

Section: Discussionsupporting

confidence: 63%

“…These findings may be a result of treatment‐related increases in glycaemic control. In patients with particularly poor glycaemic control at baseline and associated caloric loss because of glucosuria, improving glycaemic control and reducing glucosuria may lead to mitigation of weight reduction . Decreased protein turnover and reduced energy expenditure with improved glycaemic control can also lead to weight gain .…”

Section: Discussionmentioning

confidence: 99%

“…A similar pattern, with less weight loss in subjects with higher baseline HbA1c levels, was also observed with dulaglutide in the AWARD programme, 20,21 and with liraglutide. 26 These findings may be a result of treatment-related increases in glycaemic control. In patients with particularly poor glycaemic control at baseline and associated caloric loss because of glucosuria, improving glycaemic control and reducing glucosuria may lead to mitigation of weight reduction.…”

Section: Safety Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Aroda

Capehorn

Chaykin

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim To evaluate the impact of relevant patient‐level characteristics on the efficacy and safety of subcutaneous, once‐weekly semaglutide in subjects with type 2 diabetes. Materials and Methods Exploratory post hoc analyses of pooled SUSTAIN 1‐5 (phase 3a) randomized, controlled trials examined the change from baseline in HbA1c and body weight (BW), and the proportions of subjects achieving the composite endpoint (HbA1c < 7.0% [53 mmol/mol]), without weight gain or severe/blood glucose‐confirmed symptomatic hypoglycaemia at week 30 with semaglutide (0.5/1.0 mg) across clinically relevant patient subgroups: baseline HbA1c (≤7.5%, >7.5%‐8.0%, >8.0%‐8.5%, >8.5%‐9.0% and > 9.0%), background medications, diabetes duration and pancreatic beta‐cell function. Results Mean HbA1c (% point) reductions increased from lowest to highest HbA1c subgroups (−0.9%, −1.2%,‐1.5%, −1.7% and −2.3% [effect of subgroup within treatment: P = 0.247] for semaglutide 0.5 mg, and −1.1%, −1.4%, −1.9%, −2.1% and −2.7% [P = 0.045] for semaglutide 1.0 mg), with mean HbA1c ranges at week 30 of 6.3%‐7.3% and 6.1%‐6.9%, respectively. The corresponding BW reductions generally decreased with increasing baseline HbA1c (−4.4, −3.9, −3.9, −3.3 and −2.9 kg [P = 0.004], and −6.4, −5.9, −5.2, −4.5 and −4.8 kg [P < 0.001], respectively). HbA1c and BW reductions were consistently greater for semaglutide 1.0 mg versus 0.5 mg across background medication, diabetes duration and pancreatic beta‐cell function subgroups. Adverse events with semaglutide were consistent with the glucagon‐like peptide‐1 receptor agonist class, with gastrointestinal events the most common. Conclusions Semaglutide was consistently efficacious across the continuum of diabetes care in a broad spectrum of patient subgroups with a range of clinical characteristics.

show abstract

Section: Discussionsupporting

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Section: Safety Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Aroda

Capehorn

Chaykin

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…In our CGM analyses, the frequencies of hyperglycaemia were significantly decreased. The reduction in both fasting and postprandial blood glucose by Lira might contribute to the reduction in hyperglycaemia …”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes

Tonoike

Chujo

Noda

2018

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

Summary Introduction The combination of GLP‐1 receptor agonists and insulin is effective in type 2 diabetes (T2D) treatment. However, its longitudinal efficacy and safety in elderly patients have not been established. We evaluated whether liraglutide (Lira) added to insulin therapy safely improved glycaemic control in T2D patients aged >65 years. Methods Twenty T2D patients receiving insulin were recruited, and Lira was added to their treatment regimen. Before and 6 months after Lira was added, we assessed the metabolic parameters and continuous glucose monitoring (CGM) data. Results Six months after Lira was added, the levels of HbA1c and glycated albumin and body weight were significantly improved, despite the daily doses and number of insulin injections per day being reduced. CGM analysis revealed that the SD and AUC of glucose >180 mg/dL were significantly decreased; the proportion of hypoglycaemic events was not increased. Conclusion Lira administration safely improved glycaemic control and reduced body weight. Lira added to insulin therapy may improve the quality of life in elderly T2D patients undergoing insulin therapy, especially those requiring social support.

show abstract

“…The primary aim of this study was to evaluate the effects of liraglutide added to MDI on sagittal abdominal diameter, hip circumference, waist circumference, waist‐to‐hip ratio and adiponectin levels in patients with T2D enrolled in the MDI‐liraglutide trial . The hypotheses of the present study were that liraglutide reduces both hip and abdominal obesity and increases adiponectin levels in persons with T2D treated with MDI.…”

Section: Introductionmentioning

confidence: 99%

Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI‐liraglutide study 5)

Ahmadi

Filipsson

Dimenäs

et al. 2019

Obesity Science & Practice

View full text Add to dashboard Cite

Summary Aim Use of the glucagon‐like peptide 1 receptor agonist liraglutide has been shown to reduce weight. Different types of anthropometric measurements can be used to measure adiposity. This study evaluated the effect of liraglutide on sagittal abdominal diameter, waist circumference, waist‐to‐hip ratio and adiponectin levels in people with type 2 diabetes (T2D) treated with multiple daily insulin injections (MDI). Materials and methods In the multicentre, double‐blind, placebo‐controlled MDI‐liraglutide trial, 124 individuals with T2D treated with MDI were randomized to either liraglutide or placebo. Basal values of weight, waist circumference, waist‐to‐hip ratio, sagittal abdominal diameter and adiponectin were compared with measurements at 12 and 24 weeks after randomization. Results Baseline‐adjusted mean weight loss was 3.8 ± 2.9 kg greater in liraglutide than placebo‐treated individuals ( p < 0.0001). Waist circumference was reduced by 2.9 ± 4.3 cm and 0.2 ± 3.6 cm in the liraglutide and placebo groups, respectively, after 24 weeks (baseline‐adjusted mean difference: 2.6 ± 4.0 cm, p = 0.0005). Corresponding reductions in sagittal abdominal diameter were 1.1 ± 1.7 cm and 0.0 ± 1.8 cm (baseline‐adjusted mean difference: 1.1 ± 1.7 cm, p = 0.0008). Hip circumference was reduced in patients randomized to liraglutide (baseline‐adjusted mean difference between treatment groups: 2.8 ± 3.8 cm, p = 0.0001), but there was no significant difference between the groups in either waist‐to‐hip ratio (baseline‐adjusted mean difference: 0.0 ± 0.04 cm, p = 0.51) or adiponectin levels (baseline‐adjusted mean difference: 0.8 ± 3.3 mg L −1 , p = 0.17). Lower HbA1c and mean glucose levels measured by masked continuous glucose monitoring at baseline were associated with greater effects of liraglutide on reductions in waist circumference and sagittal abdominal diameter. Conclusions In patients with T2D, adding liraglutide to MDI may reduce abdominal and hip obesity to a similar extent, suggesting an effect on both visceral and subcutaneous fat. Liraglutide had greater effects on reducing abdominal obesity in patients with less pronounced long‐term hyperglycaemia but did not affect adiponectin levels.

show abstract

Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)

Cited by 19 publications

References 32 publications

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes

Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI‐liraglutide study 5)

Contact Info

Product

Resources

About